Life-threatening hemorrhage in neonates: management with recombinant activated factor VII.

Objective: Massive hemorrhage with shock is a common problem for the intensivist. The use of recombinant activated factor VII (rFVIIa), known as efficient treatment for hemophilia, has been reported to control severe bleeding episodes in critically care patients, but never in preterm neonates.

Design: Case report (two cases) and review of the literature.